Gemcitabine and Monoclonal Antibody Therapy in Treating Patients With Metastatic Cancer of the Pancreas
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00003797. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Herceptin (NSC #688097) and Gemcitabine for Metastatic Pancreatic Cancers That Overexpress HER-2/NEU
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of gemcitabine and trastuzumab in treating patients who have metastatic cancer of the pancreas that overexpresses HER2/neu.
Study identification
- NCT ID
- NCT00003797
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 41 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 1999 (Type not available)
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Dec 19, 2013
Started 1999
United States locations
- U.S. sites
- 12
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Rush-Presbyterian-St. Luke's Medical Center | Chicago | Illinois | 60612 | — |
| New England Medical Center Hospital | Boston | Massachusetts | 02111 | — |
| St. Elizabeth's Medical Center | Boston | Massachusetts | 02135-2997 | — |
| Cancer Institute of New Jersey | New Brunswick | New Jersey | 08903 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10021 | — |
| Mount Sinai Medical Center, NY | New York | New York | 10029 | — |
| University of Pittsburgh Cancer Institute | Pittsburgh | Pennsylvania | 15213-3489 | — |
| Memorial Hospital of Rhode Island | Pawtucket | Rhode Island | 02860 | — |
| Rhode Island Hospital | Providence | Rhode Island | 02903 | — |
| Roger Williams Medical Center/BUSM | Providence | Rhode Island | 02908-4735 | — |
| Brown University Oncology Group | Providence | Rhode Island | 02912 | — |
| University of Texas - MD Anderson Cancer Center | Houston | Texas | 77030-4009 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00003797, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 19, 2013 · Synced Nov 15, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.